Leserbrief
Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease
Cutis · 2023
DOI: 10.12788/cutis.0899 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cutis, 2023. Verfasst von Nicole J Levin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, University of Kansas Medical Center, Kansas City. Dr. Levin also is from the Charles E. Schmidt College of Medicine, Florida…. Hauptthemen laut MEDLINE: Eczema, Dyshidrotic, Eczema.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Eczema, DyshidroticEczemaHumansAntibodies, Monoclonal, HumanizedTreatment Outcome
Substanzen
dupilumabAntibodies, Monoclonal, Humanized
Autor:innen und Institutionen
- Division of Dermatology, University of Kansas Medical Center, Kansas City. Dr. Levin also is from the Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton.
Zitieren
APA
Levin, N. J., Seger, E. W., Neill, B. C., & Wang, T. (2023). Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease. Cutis. https://doi.org/10.12788/cutis.0899
Vancouver
Levin NJ, Seger EW, Neill BC, Wang T. Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease. Cutis. 2023. doi:10.12788/cutis.0899
BibTeX
@article{Levin2023,
author = {Levin, Nicole J and Seger, Edward W and Neill, Brett C and Wang, Ting},
title = {Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease},
journal = {Cutis},
year = {2023},
doi = {10.12788/cutis.0899}
}
EUVIMED